trial

MEtformin and Lorcaserin for WeighT Loss in Schizophrenia

NCTId NCT02796144
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Terminated
Enrollment 71 (actual)
Sponsored by University of North Carolina, Chapel Hill
Primary completion 2020-02-14
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Terminated
Enrollment
71 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2016-09
Primary completion
2020-02-14
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
LorcaserinMetformin

Sponsors

University of North Carolina, Chapel HillLead Sponsor
Columbia UniversityCollaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Collaborator

Investigators

1
Lars F. Jarskog, MDPrincipal Investigator

Sites

4 total
Augusta, United StatesNew York, United StatesChapel Hill, United StatesHillsborough, United States

Facts & assertions

4 sourced
Enrollment
71
Phase
PHASE4
Primary Completion Date
2020-02-14
Status
TERMINATED
relationships
The graph out of here
drug
Lorcaserin
drug
Metformin
drug
lead_sponsor
University of North Carolina, Chapel Hill
company
collaborator
Columbia University
company
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
company
indication
Overweight
indication
Obesity
indication
Schizoaffective Disorder
indication
investigator
Lars F. Jarskog, MD
person